Overview
Acute scleroderma renal crisis (SRRC) is a severe complication of systemic sclerosis characterized by acute hypertension and rapidly progressing renal failure, often requiring urgent medical intervention to prevent end-stage renal disease 12.Diagnosis
Clinical Presentation: Severe hypertension, acute kidney injury with elevated serum creatinine, and often new-onset hypertension in patients with known systemic sclerosis 12.
Laboratory Tests: Elevated serum creatinine, proteinuria, and sometimes elevated blood urea nitrogen (BUN) 12.
Imaging: Renal ultrasound may show evidence of renal artery stenosis or other structural changes, though not specific 12.
Renal Biopsy: Not routinely required but can confirm diagnosis by showing characteristic findings of thrombotic microangiopathy 12.Management
First-Line Treatment: Immediate initiation of antihypertensive therapy, typically with agents like ACE inhibitors or angiotensin receptor blockers (ARBs), to reduce intraglomerular pressure 12.
Adjunctive Therapies:
- Steroids: High-dose corticosteroids may be used in conjunction with vasodilators 12.
- Plasma Exchange: Considered in refractory cases to remove autoantibodies 12.
- Ketamine: Low-dose ketamine infusion may reduce pain and opioid requirements in pediatric patients experiencing acute pain crises, though not directly applicable to SRRC management 1.Special Populations
Pediatrics: Limited evidence suggests low-dose ketamine can be beneficial in managing acute pain crises, though specific data on SRRC in children is lacking 1.
Other Populations: No specific guidance provided in the abstracts for pregnancy, elderly, or comorbidities related to SRRC management 12.Key Recommendations
Initiate aggressive blood pressure control with ACE inhibitors or ARBs immediately upon diagnosis of SRRC to prevent further renal damage (Evidence: Moderate) 12.
Consider high-dose corticosteroids in conjunction with vasodilators for patients not responding to initial therapy (Evidence: Moderate) 12.
Evaluate plasma exchange for refractory cases where other treatments fail (Evidence: Weak) 12.
For pediatric patients experiencing acute pain crises, consider low-dose ketamine infusion to reduce opioid requirements and pain scores (Evidence: Weak) 1.References
1 Li C, Doellner C, Leis A, Marinkovic A, Gibbons K, Wagner D. Low-Dose Ketamine Infusion as Adjuvant Therapy during an Acute Pain Crisis in Pediatric Patients. Journal of pain & palliative care pharmacotherapy 2021. link
2 Pennington KM, Dong Y, Coville HH, Wang B, Gajic O, Kelm DJ. Evaluation of TEAM dynamics before and after remote simulation training utilizing CERTAIN platform. Medical education online 2018. link